Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rocket Pharmaceuticals (DE:9IP1)
MUNICH:9IP1
RESEARCH TOOLSreports
Rocket Pharmaceuticals (9IP1) Ownership - Who Owns Rocket Pharmaceuticals?
0 Followers
Rocket Pharmaceuticals (9IP1) Ownership Overview
0.00% Insiders
0.00% Mutual Funds
2.60% Other Institutional Investors
97.40% Public Companies and
Individual Investors
The ownership structure of Rocket Pharmaceuticals (DE:9IP1) stock is a mix of institutional, retail and individual investors. Approximately 2.60% of the company’s stock is owned by Institutional Investors, 0.00% is owned by Insiders and 97.40% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
Date | Name | Activity | Value |
|---|---|---|---|
| Apr 24, 2024 | John Militello Vp Of Finance, Treasurer, Principal Accounting Officer | Sold | $19051 |
| Apr 10, 2024 | Mark Andrew White General Manager, Commercial Affairs | Sold | $308663 |
| Mar 25, 2024 | John Militello Vp Of Finance, Treasurer, Principal Accounting Officer | Sold | $69969 |
| Mar 25, 2024 | Gotham Makker Director | Sold | $7789820 |
Recent Hedge Fund Trading Activity
Date | Firm | Activity | Value |
|---|---|---|---|
| Dec 31, 2023 | Bought | $580788 | |
| Dec 31, 2023 | Sold | $9185805 | |
| Dec 31, 2023 | Bought | $51170718 | |
| Dec 31, 2023 | Sold | $120901017 |
Top Shareholders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 2,277,139 | Insider | ― | 48,503,061 | |
| 114,784 | Insider | ― | 2,444,899 | |
| 2,277,139 | Insider | ― | 48,503,061 | |
| 3,253,566 | Insider | ― | 69,300,956 | |
| 3,243,709 | Insider | ― | 69,091,002 | |
| 1,917,906 | Insider | ― | 40,851,398 | |
| 3,243,709 | Insider | ― | 69,091,002 | |
| 2,870,584 | Insider | ― | 61,143,439 | |
| 1,292,584 | Insider | ― | 27,532,039 | |
| 268,718 | Institution | ― | 6,165,197 |
Top Mutual Fund Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 668,660 | Institution | ― | 15,341,066 | |
| 107,713 | Institution | ― | 2,471,259 | |
| 8,797 | Institution | ― | 201,838 | |
| 53,091 | Institution | ― | 1,218,057 | |
| 8,017 | Institution | ― | 183,934 | |
| 286,029 | Institution | ― | 6,562,363 | |
| 139,305 | Institution | ― | 3,196,075 | |
| 125,318 | Institution | ― | 2,875,171 | |
| 196,016 | Institution | ― | 4,497,195 | |
| 120 | Institution | ― | 2,753 |
Top ETF Holders
Holder | # of Shares | Type | % Holding | Value |
|---|
FAQ
Who Owns Rocket Pharmaceuticals (DE:9IP1)?
According to the latest TipRanks data, approximately 2.60% of the company's stock is held by institutional investors, 0.00% is held by insiders, and 97.40% is held by retail investors.
What percentage of Rocket Pharmaceuticals (DE:9IP1) stock is held by institutional investors?
According to the latest TipRanks data, approximately 2.60% of Rocket Pharmaceuticals (DE:9IP1) stock is held by institutional investors.
What percentage of Rocket Pharmaceuticals (DE:9IP1) stock is held by retail investors?
According to the latest TipRanks data, approximately 97.40% of Rocket Pharmaceuticals (DE:9IP1) stock is held by retail investors.
Who owns the most shares of Rocket Pharmaceuticals (DE:9IP1)?
Argeris Karabelas owns the most shares of Rocket Pharmaceuticals (DE:9IP1).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.